SillaJen, Inc. (KOSDAQ:215600)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,465.00
+275.00 (12.56%)
Jun 29, 2026, 3:30 PM KST
Market Cap341.53B -25.1%
Revenue (ttm)10.92B +128.4%
Net Income-24.13B
EPS-174.91
Shares Out 138.55M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume724,279
Open2,190.00
Previous Close2,190.00
Day's Range2,190.00 - 2,475.00
52-Week Range2,185.00 - 5,400.00
Beta-0.05
Analystsn/a
Price Targetn/a
Earnings DateAug 13, 2026

About SillaJen

SillaJen, Inc., together with its subsidiaries, engages in developing technologies and products using genetic engineering in South Korea. Its clinical pipeline includes Pexa-Vec, which is in phase 2 clinical trial to treat renal cell carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors. The company also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-600 Series and JX-970 to treat solid tumors and is in preclinical trial. In addition, it operates in... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 57
Stock Exchange KOSDAQ
Ticker Symbol 215600
Full Company Profile

Financial Performance

In 2025, SillaJen's revenue was 9.23 billion, an increase of 134.94% compared to the previous year's 3.93 billion. Losses were -24.19 billion, -8.81% less than in 2024.

Financial Statements